Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Daratumumab + Dexamethasone + Lenalidomide + Selinexor|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 13||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Selinexor||Xpovio||KPT-330||Xpovio (selinexor) inhibits CRM1 (XPO1), preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (PMID: 30976603, PMID: 31793336). Xpovio (selinexor) is FDA approved for use in patients with diffuse large B cell lymphoma after two or more prior therapies, in combination with Adexone (dexamethasone) in patients with relapsed or refractory multiple myeloma after at least four prior therapies, and in combination with Velcade (bortezomib) and Adexone (dexamethasone) in patients with multiple myeloma after at least one prior therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04782687||Phase II||Daratumumab + Dexamethasone + Lenalidomide + Selinexor||Phase II Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma||Recruiting||USA||0|